...
首页> 外文期刊>Journal of the American Society of Nephrology: JASN >Reduction of Dialysate Calcium Level Reduces Progression of Coronary Artery Calcification and Improves Low Bone Turnover in Patients on Hemodialysis
【24h】

Reduction of Dialysate Calcium Level Reduces Progression of Coronary Artery Calcification and Improves Low Bone Turnover in Patients on Hemodialysis

机译:减少透析液钙水平降低了冠状动脉钙化的进展,提高了血液透析患者的低骨周转

获取原文
获取原文并翻译 | 示例
           

摘要

Exposure to high Ca concentrations may influence the development of low-turnover bone disease and coronary artery calcification (CAC) in patients on hemodialysis (HD). In this randomized, controlled study, we investigated the effects of lowering dialysate Ca level on progression of CAC and histologic bone abnormalities in patients on HD. Patients on HD with intact parathyroid hormone levels <= 300 pg/ml receiving dialysate containing 1.75 or 1.50 mmol/L Ca (n=425) were randomized to the 1.25-mmol/L Ca (1.25 Ca; n=212) or the 1.75-mmol/L Ca (1.75 Ca; n=213) dialysate arm. Primary outcome was a change in CAC score measured by multislice computerized tomography; main secondary outcome was a change in bone histomorphometric parameters determined by analysis of bone biopsy specimens. CAC scores increased from 452 +/- 89 (mean +/- SD) in the 1.25 Ca group and 500 +/- 909 in the 1.75 Ca group (P=0.68) at baseline to 616 +/- 1086 and 803 +/- 1412, respectively, at 24 months (P=0.25). Progression rate was significantly lower in the 1.25 Ca group than in the 1.75 Ca group (P=0.03). The prevalence of histologically diagnosed low bone turnover decreased from 85.0% to 41.8% in the 1.25 Ca group (P=0.001) and did not change in the 1.75 Ca group. At 24 months, bone formation rate, trabecular thickness, and bone volume were higher in the 1.25 Ca group than in the 1.75 Ca group. Thus, lowering dialysate Ca levels slowed the progression of CAC and improved bone turnover in patients on HD with baseline intact parathyroid hormone levels <= 300 pg/ml.
机译:暴露于高Ca浓度可能影响血液透析(HD)患者的低端骨病和冠状动脉钙化(CAC)的发育。在这种随机对照研究中,我们研究了降低透析液Ca水平对高清患者CAC和组织学骨异常的进展的影响。 HD患者具有完整的甲状旁腺激素水平<= 300pg / ml接受含有1.75或1.50mmol / L Ca(n = 425)的透析酸盐的患者被随机化为1.25mmol / l Ca(1.25 ca; n = 212)或1.75 -mmol / l Ca(1.75 ca; n = 213)透析型臂。主要结果是通过多层计算机断层扫描测量的CAC评分的变化;主要二次结果是通过分析骨活检标本确定的骨组织形态学参数的变化。 CAC分数从1.25 CA组的452 +/- 89(平均+/- SD)增加1.75 CA组(P = 0.68)的1.75 CA组(P = 0.68)到616 +/- 1086和803 +/-分别在24个月(p = 0.25)分别为1412。 1.25 Ca组进展速率明显低于1.75 Ca组(P = 0.03)。组织学诊断的低骨周转的患病率从1.25CA组(P = 0.001)中的85.0%降至41.8%,并在1.75 CA组中没有变化。在24个月,1.25ca组中,骨形成速率,骨形成率,骨厚度和骨体积高于1.75 Ca组。因此,降低透析液Ca水平减缓了CAC的进展和高清患者的患者的骨质周转,基线完整甲状旁腺激素水平<= 300 pg / ml。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号